PolyNovo (ASX:PNV) has announced that Professor Toby Coates AO, the director of Beta Cell Technologies, has presented the results of the company's NovoSorb and its potential role in treating and managing Type 1 diabetes.

Point-of-care diagnostic technology company Lumos Diagnostics (ASX:LDX) states that it has received a purchase order and shipped the product for FebriDx to iMedical.

Prime Minister Anthony Albanese has appointed Senator Tim Ayres to the industry, innovation and science portfolios.

EnGeneIC has announced the dosing of the first patient in its open-label, multicentre, Phase I/IIa clinical trial at Mater Hospital in Sydney.

PolyNovo (ASX:PNV) has announced that its NovoSorb MTX (4 mm, 6 mm) has received TGA clearance, following the regulator's clearance of the 2 mm product in March. 

A team of Melbourne scientists has been backed by the Australian Government’s Medical Research Future Fund Stem Cell Therapies Mission to support their development of potential new medicines to treat dementia.

Radiopharm Theranostics (ASX:RAD) has achieved a milestone in its ongoing clinical development program for its radiotherapeutic asset, 177Lu-RAD204.

Clinical-stage company Tryptamine Therapeutics (ASX:TYP) has announced the appointment of Herwig Janssen as its non-executive chairman.

OncoSil Medical managing director and CEO Nigel Lange said, “The results of this important analysis highlight the superiority of the OncoSil device compared to Stereotactic Body Radiation Therapy, which is considered to be the best available system for delivering external beam radiotherapy to patients with locally advanced pancreatic cancer."

Percheron Therapeutics (ASX:PER) has lodged a prospectus for a pro-rata non-renounceable bonus offer of unquoted options to acquire loyalty options to eligible shareholders.

Neuren Pharmaceuticals (ASX:NEU) has updated investors on the first quarter 2025 financial results announcement and conference call of its partner Acadia Pharmaceuticals.

Algorae Pharmaceuticals (ASX:1AI) has agreed with the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre to validate AI-predicted drug synergies through high-throughput screening.

LTR Pharma (ASX:LTP) has entered a collaborative development agreement with Strategic Drug Solutions to co-develop OROFLOW, a novel intranasal spray targeting Oesophageal Motility Disorders.

AusBiotech CEO Rebekah Cassidy said the investor-focused event will help accelerate the delivery of real-world, home-grown health solutions.

Immutep (ASX:IMM) has announced positive results from a Phase 2b trial of its eftilagimod alfa (efti) in combination with MSD's KEYTRUDA (pembrolizumab) for head and neck cancer.

AusBiotech has signed a partnership agreement with digital health commercialisation specialist ANDHealth to enhance collaboration on mutual interests and support ongoing industry innovation.

Alterity Therapeutics (ASX:ATH) has announced that the US FDA has granted fast track designation for ATH434 for treating Multiple System Atrophy.